Is CGTX or SNTI more profitable?

Cognition Therapeutics' return on equity of -72.68% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Senti Biosciences N/A -532.05% -103.35%

Is SNTI or ENGN more profitable?

enGene's return on equity of -55.83% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% enGene N/A -55.83% -45.74%

Do analysts rate SNTI or CUE?

Senti Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 927.75%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Senti Biosciences is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend AADI or SNTI?

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 927.75%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Senti Biosciences (SNTI) Competitors

$0.97 +0.03 (+3.33%)

As of 09:56 AM Eastern

Compare

SNTI vs. CGTX, ENGN, CUE, COYA, and AADI

Should you buy Senti Biosciences stock or one of its competitors? MarketBeat compares Senti Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Senti Biosciences include Cognition Therapeutics (CGTX), enGene (ENGN), Cue Biopharma (CUE), Coya Therapeutics (COYA), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

How does Senti Biosciences compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Cognition Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Senti Biosciences	$38K	797.48	-$61.44M	-$1.92	N/A

Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 178.94%. Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 927.75%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Cognition Therapeutics had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Cognition Therapeutics and 0 mentions for Senti Biosciences. Cognition Therapeutics' average media sentiment score of 0.86 beat Senti Biosciences' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
Senti Biosciences	Neutral

43.3% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cognition Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Cognition Therapeutics' return on equity of -72.68% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Senti Biosciences	N/A	-532.05%	-103.35%

Summary

Cognition Therapeutics beats Senti Biosciences on 9 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to enGene?

Senti Biosciences (NASDAQ:SNTI) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Senti Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 927.75%. enGene has a consensus target price of $12.68, suggesting a potential upside of 658.03%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Senti Biosciences is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

enGene's return on equity of -55.83% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
enGene	N/A	-55.83%	-45.74%

Senti Biosciences has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, enGene has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

In the previous week, enGene had 13 more articles in the media than Senti Biosciences. MarketBeat recorded 13 mentions for enGene and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 beat enGene's score of -0.06 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Neutral
enGene	Neutral

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Senti Biosciences has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$38K	797.48	-$61.44M	-$1.92	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

Summary

Senti Biosciences beats enGene on 9 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Cue Biopharma?

Senti Biosciences (NASDAQ:SNTI) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Cue Biopharma has higher revenue and earnings than Senti Biosciences. Cue Biopharma is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$38K	797.48	-$61.44M	-$1.92	N/A
Cue Biopharma	$27.47M	4.70	-$26.60M	-$5.58	N/A

Senti Biosciences has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.51, meaning that its stock price is 151% more volatile than the broader market.

Senti Biosciences has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Cue Biopharma	-59.65%	-98.30%	-53.69%

In the previous week, Cue Biopharma had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Cue Biopharma and 0 mentions for Senti Biosciences. Cue Biopharma's average media sentiment score of 0.31 beat Senti Biosciences' score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Senti Biosciences	Neutral
Cue Biopharma	Neutral

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Senti Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 927.75%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Senti Biosciences is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cue Biopharma beats Senti Biosciences on 9 of the 17 factors compared between the two stocks.

How does Senti Biosciences compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Senti Biosciences has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Senti Biosciences	N/A	-532.05%	-103.35%

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 228.34%. Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 927.75%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Coya Therapeutics had 3 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Coya Therapeutics and 0 mentions for Senti Biosciences. Coya Therapeutics' average media sentiment score of 0.33 beat Senti Biosciences' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Neutral
Senti Biosciences	Neutral

Coya Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Coya Therapeutics has higher revenue and earnings than Senti Biosciences. Coya Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.94M	13.80	-$21.23M	-$1.15	N/A
Senti Biosciences	$38K	797.48	-$61.44M	-$1.92	N/A

Summary

Coya Therapeutics beats Senti Biosciences on 10 of the 17 factors compared between the two stocks.

How does Senti Biosciences compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Senti Biosciences has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Senti Biosciences	N/A	-532.05%	-103.35%

In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Senti Biosciences	Neutral

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Senti Biosciences has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.96	-$65.76M	-$2.35	N/A
Senti Biosciences	$38K	797.48	-$61.44M	-$1.92	N/A

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 927.75%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Summary

Senti Biosciences beats Aadi Bioscience on 10 of the 15 factors compared between the two stocks.

Get Senti Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNTI vs. The Competition

Export

Metric	Senti Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.30M	$3.34B	$6.47B	$11.98B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	-0.51	18.61	23.69	23.74
Price / Sales	797.48	306.89	533.79	119.57
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	5.41	8.04	10.36	6.78
Net Income	-$61.44M	$23.89M	$3.57B	$337.51M
7 Day Performance	-1.10%	-3.28%	0.27%	-2.34%
1 Month Performance	-1.30%	2.78%	3.26%	1.88%
1 Year Performance	-68.81%	36.03%	22.22%	25.55%

Senti Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNTI Senti Biosciences	2.3878 of 5 stars	$0.97 +3.3%	$10.00 +927.7%	-75.5%	$30.30M	$38K	N/A	4
CGTX Cognition Therapeutics	3.8842 of 5 stars	$1.35 +8.0%	$3.33 +146.9%	+309.8%	$120.83M	N/A	N/A	20	Positive News Gap Down High Trading Volume
ENGN enGene	4.1124 of 5 stars	$1.74 -2.2%	$12.68 +628.8%	-56.3%	$116.55M	N/A	N/A	31	Upcoming Earnings
CUE Cue Biopharma	0.5623 of 5 stars	$28.62 +18.9%	N/A	-95.0%	$115.80M	$32.73M	N/A	60	Analyst Upgrade
COYA Coya Therapeutics	3.1349 of 5 stars	$4.73 -3.7%	$16.00 +238.3%	-22.6%	$110.97M	$7.95M	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNTI) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Senti Biosciences (SNTI) Competitors

SNTI vs. CGTX, ENGN, CUE, COYA, and AADI

How does Senti Biosciences compare to Cognition Therapeutics?

Summary

How does Senti Biosciences compare to enGene?

Summary

How does Senti Biosciences compare to Cue Biopharma?

Summary

How does Senti Biosciences compare to Coya Therapeutics?

Summary

How does Senti Biosciences compare to Aadi Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Senti Biosciences (SNTI) Competitors

SNTI vs. CGTX, ENGN, CUE, COYA, and AADI

How does Senti Biosciences compare to Cognition Therapeutics?

Which has better earnings and valuation, CGTX or SNTI?

Do analysts prefer CGTX or SNTI?

Does the media favor CGTX or SNTI?

Do insiders and institutionals hold more shares of CGTX or SNTI?

Which has more risk & volatility, CGTX or SNTI?

Is CGTX or SNTI more profitable?

Summary

How does Senti Biosciences compare to enGene?

Do analysts rate SNTI or ENGN?

Is SNTI or ENGN more profitable?

Which has more volatility & risk, SNTI or ENGN?

Does the media refer more to SNTI or ENGN?

Do insiders & institutionals hold more shares of SNTI or ENGN?

Which has better earnings and valuation, SNTI or ENGN?

Summary

How does Senti Biosciences compare to Cue Biopharma?

Which has preferable earnings and valuation, SNTI or CUE?

Which has more volatility and risk, SNTI or CUE?

Is SNTI or CUE more profitable?

Does the media refer more to SNTI or CUE?

Do insiders and institutionals have more ownership in SNTI or CUE?

Do analysts rate SNTI or CUE?

Summary

How does Senti Biosciences compare to Coya Therapeutics?

Do insiders & institutionals believe in COYA or SNTI?

Is COYA or SNTI more profitable?

Do analysts rate COYA or SNTI?

Does the media favor COYA or SNTI?

Which has more volatility & risk, COYA or SNTI?

Which has higher earnings and valuation, COYA or SNTI?

Summary

How does Senti Biosciences compare to Aadi Bioscience?

Is AADI or SNTI more profitable?

Does the media favor AADI or SNTI?

Do insiders & institutionals have more ownership in AADI or SNTI?

Which has higher valuation & earnings, AADI or SNTI?

Do analysts recommend AADI or SNTI?

Which has more volatility and risk, AADI or SNTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools